Mary M Horowitz
Overview
Explore the profile of Mary M Horowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
248
Citations
12141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kassim A, Walters M, Eapen M, Smith M, Logan B, Solh M, et al.
NEJM Evid
. 2025 Feb;
4(3):EVIDoa2400192.
PMID: 39998298
Background: Related human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with posttransplant cyclophosphamide may be curative for sickle cell disease. However, graft failure, severe graft-versus-host disease (GVHD), infections, and mortality...
2.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
3.
Holtan S, Bolanos-Meade J, Al Malki M, Wu J, Kitko C, Reshef R, et al.
J Clin Oncol
. 2025 Jan;
43(8):912-918.
PMID: 39752608
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS)...
4.
Kaur M, Horowitz M, Mendizabal A, Chen M, Foley A, Auletta J, et al.
Transplant Cell Ther
. 2024 Nov;
31(1):49-57.
PMID: 39489220
Underrepresentation by race and ethnicity in oncology clinical trials, including those of hematopoietic cell transplantation (HCT), is a known challenge. This analysis studied accrual on Blood and Marrow Transplant Clinical...
5.
Eapen M, Antin J, Tolar J, Arai S, Horwitz M, Kou J, et al.
EClinicalMedicine
. 2024 Sep;
76:102819.
PMID: 39290639
Background: Almost all acquired severe aplastic anaemia is immune mediated and characterised by hypocellular bone marrow and ≥2 affected haematopoietic lineages. The optimal preparartive regimen for unrelated donor transplantation remains...
6.
Hamilton B, Pandya B, Ivanescu C, Elsouda D, Hamadani M, Chen Y, et al.
Blood Adv
. 2024 Aug;
8(19):5091-5099.
PMID: 39167766
The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia...
7.
Levis M, Hamadani M, Horowitz M, Chen Y
J Clin Oncol
. 2024 Jul;
42(32):3881-3882.
PMID: 39083722
No abstract available.
8.
Hill J, Martens M, Young J, Bhavsar K, Kou J, Chen M, et al.
Clin Infect Dis
. 2024 May;
79(2):542-554.
PMID: 38801746
Background: The optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether...
9.
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos J, Iida M, et al.
Haematologica
. 2024 May;
109(10):3282-3294.
PMID: 38721749
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for...
10.
Pasquini M, Wallace P, Logan B, Kaur M, Tario J, Howard A, et al.
J Clin Oncol
. 2024 May;
42(23):2757-2768.
PMID: 38701390
Purpose: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on...